Lenz Therapeutics has earned the FDA’s go-ahead for its aceclidine eye drop to crack the large presbyopia market, where past ...

Chardan Research and William Blair have both issued positive outlooks on Alnylam following the second-quarter results.

Despite the overall decline in commercial product revenue, Moderna was also pleasantly surprised by Q2 Spikevax sales, which ...

We continue to feel confident about our ability to capture 90%," LPL CEO Rich Steinmeier told analysts during the firm's 2nd ...

Vertiv Holdings (NYSE:VRT) on Monday was rated Outperform in new research coverage by analysts at investment firm William ...

Jed Dorsheimer, William Blair analyst, joins 'The Exchange' to discuss Tesla's chip deal with Samsung and what it means for ...

Avantor missed Q2 EPS expectations as weak bioprocessing sales and customer disruptions pressured earnings, despite flat organic growth and a CEO change.

CyberArk Software Ltd. (NASDAQ:CYBR) is one of the 10 AI Stocks Investors Should Keep an Eye On. On July 30, William Blair ...

In addition, The Allstate Corporation (NYSE:ALL) is taking advantage of a far better auto loss environment and employing ...

William Blair is increasingly known for its prominence in the asset management business, with a global footprint of more than $81.9 billion¹ in client assets as of December 31, 2018.

Mastercard eased concerns about a potential slowdown in consumer spending after beating Wall Street estimates for ...